Alterity Therapeutics Ltd Stock Price, News & Analysis

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has expanded its Phase 2 clinical trial for ATH434, now recruiting in Australia, the United States, and Italy. The company presented significant bioMUSE data at two key industry conferences and secured a 20-year patent for over 100 compounds targeting neurological diseases like Parkinson's and Alzheimer's. As of December 31, 2022, Alterity reported a cash balance of A$25.3M with A$5.2M in operational cash outflows. The company aims to support early-stage MSA patients with promising therapeutic options.

Alterity Therapeutics (NASDAQ: ATHE) announced the opening of enrollment for its Phase 2 clinical trial of ATH434, targeting Multiple System Atrophy (MSA). Conducted at Vanderbilt University, the trial aims to recruit approximately 60 participants to assess ATH434's efficacy as a disease-modifying treatment. This study employs neuroimaging and motor assessments to evaluate treatment impacts over 12 months, marking a significant milestone as the U.S. joins Europe and Asia-Pacific in recruitment efforts. ATH434, an oral agent, is designed to inhibit protein aggregation in neurodegenerative diseases.

Alterity Therapeutics Limited (NASDAQ: ATHE) announced a 1-for-10 reverse split of its American Depository Shares (ADS), effective January 9, 2023. The ADS Ratio will change from 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares. This adjustment aims to help the company regain compliance with NASDAQ's minimum bid price of $1.00 per share by February 23, 2023. No fractional ADSs will be issued; instead, fractional entitlements will be sold, and net proceeds distributed to shareholders. The company's ADS will trade on a split-adjusted basis under a new CUSIP number.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that CEO David Stamler will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum on January 8, 2022, during the J.P. Morgan Healthcare Conference. Dr. Stamler will join a panel titled 'New Approaches to Parkinson's and Movement Disorders,' provide a company update, and engage in investor meetings. The forum will address global bio-partnering advancements and scientific developments in neurodegenerative diseases, which includes key areas like neuropsychiatry and digital therapeutics.

Alterity Therapeutics (NASDAQ: ATHE) announced the allowance of a new composition of matter patent by the USPTO, granting 20 years of exclusivity. This patent covers over 100 novel compounds aimed at treating neurodegenerative diseases, particularly Alzheimer's and Parkinson's. Importantly, the compounds include iron chaperones that address excess iron in the brain, linked to these diseases. CEO David Stamler emphasized this expansion of their intellectual property and the potential of lead asset ATH434 currently in Phase 2 trials.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a poster presentation from the bioMUSE study at the AAS 2022 Annual Conference held November 2-5, 2022, focusing on urinary symptoms in early Multiple System Atrophy (MSA). This is the first evaluation of urinary symptoms using the Urinary Symptom Profile (USP) in MSA patients. The study involved 16 participants, showing significant urinary issues like urgency and frequency. Alterity's lead candidate, ATH434, aims to treat MSA and has shown promise in preclinical studies, receiving Orphan designation from the U.S. FDA.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announces the dosing of the first patient in its Phase 2 clinical trial for ATH434, aimed at treating Multiple System Atrophy (MSA). The trial has expanded to Europe, Australia, and has received FDA approval to commence in the U.S. As of September 30, 2022, the company reported a cash balance of A$31.9M and an operating cash outflow of A$4.8M, driven by clinical advancement. The randomized trial is set to enroll around 60 patients over 12 months to evaluate efficacy endpoints, enhancing prospects for a future Phase 3 study.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a poster presentation from its ongoing bioMUSE natural history study at the 147th Annual Meeting of the American Neurological Association on October 24, 2022. The study revealed that deep learning segmentation improves MRI accuracy in assessing brain structures affected by Multiple System Atrophy (MSA). The research involved 21 MSA patients and highlighted significant volume reductions in the brain regions compared to healthy controls. Alterity's lead candidate, ATH434, shows promise in treating neurodegenerative diseases, having completed successful Phase 1 trials.

Alterity Therapeutics has announced the approval of its Phase 2 clinical trial for ATH434 in Australia, targeting Multiple System Atrophy (MSA). The trial aims to assess the efficacy and safety of ATH434 in early-stage MSA patients through a randomized, double-blind, placebo-controlled study. Approximately 60 participants will receive treatment for 12 months, focusing on neuroimaging and protein biomarkers. This trial marks a significant step for Alterity, which has regulatory clearance in five countries for this study.